We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

Back to rankings

38 hedge funds and large institutions have $161M invested in Strongbridge Biopharma plc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

475% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 4

100% more funds holding

Funds holding: 19 → 38 (+19)

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

62% more capital invested

Capital invested by funds: $99.4M → $161M (+$61.4M)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
38
Holders Change
+19
Holders Change %
+100%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
23
Increased
4
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4M
2
Northern Trust
Northern Trust
Illinois
+$945K
3
NC
Nexthera Capital
New York
+$309K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$307K
5
TCIM
TIAA CREF Investment Management
New York
+$290K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$507K
2
GPCM
Granite Point Capital Management
Massachusetts
-$125K
3
Millennium Management
Millennium Management
New York
-$104K
4
SIM
Spark Investment Management
New York
-$91K
5
Barclays
Barclays
United Kingdom
-$70.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
CC
1
Caxton Corporation
New Jersey
$38.6M – – –
NMC
2
NEA Management Company
Maryland
$29.6M – – –
VC
3
Vivo Capital
California
$21.4M – – –
BC
4
Broadfin Capital
New York
$20.5M -$507K -109,778 -4%
AC
5
Armistice Capital
New York
$12.1M +$240K +52,000 +3%
OM
6
Opaleye Management
Massachusetts
$8.44M – – –
BC
7
Boxer Capital
California
$6.72M – – –
TAF
8
Tredje AP-fonden
Sweden
$6.5M – – –
BlackRock
9
BlackRock
New York
$6.44M +$4M +865,594 +2,493%
GPCM
10
Granite Point Capital Management
Massachusetts
$4.06M -$125K -27,133 -5%
Northern Trust
11
Northern Trust
Illinois
$1.46M +$945K +204,519 New
NC
12
Nexthera Capital
New York
$477K +$309K +66,756 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$474K +$307K +66,378 New
TCIM
14
TIAA CREF Investment Management
New York
$449K +$290K +62,791 New
State Street
15
State Street
Massachusetts
$443K +$287K +62,106 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$436K +$213K +46,052 +307%
Citigroup
17
Citigroup
New York
$338K +$218K +47,241 New
Charles Schwab
18
Charles Schwab
California
$332K +$214K +46,400 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$331K +$213K +46,171 New
TA
20
Teachers Advisors
New York
$297K +$192K +41,486 New
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$277K +$179K +38,800 New
Deutsche Bank
22
Deutsche Bank
Germany
$178K +$116K +25,157 New
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$154K +$99.5K +21,526 New
Morgan Stanley
24
Morgan Stanley
New York
$145K +$72.3K +15,643 +340%
State of Wisconsin Investment Board
25
State of Wisconsin Investment Board
Wisconsin
$114K +$74K +16,000 New
1
2

SBBP Hedge Fund Activity: Q2 2017 in Review

38 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q2 2017, worth a combined $161M — up 62% from $99.4M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new SBBP positions and 4 closed out — a net gain of 19 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $4M. The largest seller was Broadfin Capital, cutting an estimated $507K.

  • 38 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q2 2017, up from 19 in Q1 2017.
  • Funds reported $161M of Strongbridge Biopharma plc. stock for Q2 2017, up 62% quarter-over-quarter.
  • 23 funds opened new Strongbridge Biopharma plc. positions in Q2 2017 and 4 closed out, a net change of +19 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q2 2017 was BlackRock, an estimated $4M added.
  • The largest Strongbridge Biopharma plc. seller in Q2 2017 was Broadfin Capital, an estimated $507K sold.

Based on aggregated 13F filings for Q2 2017.